Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs

被引:44
作者
Stelling, JM
Travers, K
Jones, RN
Turner, PJ
O'Brien, TF
Levy, SB
机构
[1] Brigham & Womens Hosp, Microbiol Lab, Boston, MA 02115 USA
[2] Alliance Prudent Use Antibiot, Boston, MA USA
[3] Jones Grp, N Liberty, IA USA
[4] Tufts Univ, Boston, MA 02111 USA
[5] AstraZeneca, Macclesfield, Cheshire, England
关键词
D O I
10.3201/eid1106.041160
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Collaboration between networks presents opportunities to increase analytical power and cross-validate findings. Multivariate analyses of 2 large, international datasets (MYSTIC and SENTRY) from the Global Advisory on Antibiotic Resistance Data program explored temporal, geographic, and demographic trends in Escherichia coli resistance from 1997 to 2001. Elevated rates of nonsusceptibility were seen in Latin America, southern Europe, and the western Pacific, and lower rates were seen in North America. For most antimicrobial drugs considered, nonsusceptibility was higher in isolates from men, older patients, and intensive care unit patients. Nonsusceptibility to ciprofloxacin was higher in younger patients, rose with time, and was not associated with intensive care unit status. In univariate analyses, estimates of nonsusceptibility from MYSTIC were consistently higher than those from SENTRY, but these differences disappeared in multivariate analyses, which supports the epidemiologic relevance of findings from the 2 programs, despite differences in surveillance strategies.
引用
收藏
页码:873 / 882
页数:10
相关论文
共 36 条
  • [1] *ALL PRUD US ANT, 1999, APUA RES SURV
  • [2] [Anonymous], 2001, WHO GLOB STRAT CONT
  • [3] Bavestrello L, 2002, REV MED CHILE, V130, P1265
  • [4] Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002)
    Biedenbach, DJ
    Moet, GJ
    Jones, RN
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 50 (01) : 59 - 69
  • [5] Current issues in the management of urinary tract infections - Extended-release ciprofloxacin as a novel treatment option
    Blondeau, JM
    [J]. DRUGS, 2004, 64 (06) : 611 - 628
  • [6] Diekema DJ, 1999, CLIN INFECT DIS, V29, P595, DOI 10.1086/598640
  • [7] Fenwick EAL, 2000, BRIT J GEN PRACT, V50, P635
  • [8] Bacterial resistance - the clinical challenge
    Finch, R
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 : 21 - 32
  • [9] Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998
    Fluit, AC
    Jones, ME
    Schmitz, FJ
    Acar, J
    Gupta, R
    Verhoef, J
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (03) : 454 - 460
  • [10] Emergence and dissemination of quinolone-resistant Escherichia coli in the community
    Garau, J
    Xercavins, M
    Rodríguez-Carballeira, M
    Gómez-Vera, JR
    Coll, I
    Vidal, D
    Llovet, T
    Ruíz-Bremón, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) : 2736 - 2741